
|Videos|June 6, 2023
Approved PSMA-PET Imaging Tracer Options for Prostate Cancer
The panel reviews the similarities and differences between the FDA-approved PSMA-PET tracer options for prostate cancer imaging.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5
















